Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN
· Results of an investigator-initiated open-label Phase 2 study of imlifidase in patients with anti-glomerular basement membrane (anti-GBM) disease published in leading nephrology publication Journal of the American Society of Nephrology (JASN).1 · Imlifidase rapidly and completely reduced pathogenic anti-GBM antibody levels to below reference range. · At six months 67% of the included patients had functioning kidneys versus 18% in a historical control cohort. · The publication recognises the study’s significance in autoimmune diseases as it suggests that deactivation of
